GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
NASDAQ:CNAT
Delisted

Conatus Pharmaceuticals Inc. Stock Price (Quote)

$0.255
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $0.255 $0.255 Friday, 27th May 2022 CNAT stock ended at $0.255. During the day the stock fluctuated 0% from a day low at $0.255 to a day high of $0.255.
90 days $0.238 $0.275
52 weeks $0.203 $1.23

Historical Conatus Pharmaceuticals Inc. prices

Date Open High Low Close Volume
2019-03-27 $1.24 $1.24 $1.12 $1.14 1 288 513
2019-03-26 $1.21 $1.24 $1.14 $1.21 1 077 630
2019-03-25 $1.27 $1.28 $1.18 $1.20 1 864 613
2019-03-22 $1.35 $1.39 $1.21 $1.28 6 068 912
2019-03-21 $2.89 $3.08 $2.78 $2.91 2 715 855
2019-03-20 $2.86 $2.96 $2.81 $2.88 462 205
2019-03-19 $2.93 $3.00 $2.72 $2.87 700 016
2019-03-18 $2.70 $2.91 $2.60 $2.89 949 900
2019-03-15 $2.69 $2.81 $2.56 $2.67 1 376 097
2019-03-14 $2.97 $3.01 $2.66 $2.85 1 860 214
2019-03-13 $2.34 $3.02 $2.27 $2.89 5 052 195
2019-03-12 $2.13 $2.43 $2.07 $2.30 1 801 518
2019-03-11 $2.06 $2.28 $2.00 $2.10 1 756 731
2019-03-08 $2.00 $2.07 $1.92 $1.97 509 608
2019-03-07 $2.05 $2.05 $1.97 $2.01 516 601
2019-03-06 $2.20 $2.24 $1.95 $2.03 624 825
2019-03-05 $2.21 $2.24 $2.12 $2.19 321 524
2019-03-04 $2.14 $2.24 $2.09 $2.18 445 739
2019-03-01 $1.94 $2.28 $1.94 $2.12 1 106 999
2019-02-28 $1.97 $1.98 $1.90 $1.94 290 773
2019-02-27 $1.98 $2.05 $1.96 $1.99 307 890
2019-02-26 $1.94 $2.02 $1.91 $2.00 564 114
2019-02-25 $1.89 $1.99 $1.89 $1.94 377 030
2019-02-22 $1.89 $1.95 $1.87 $1.88 303 326
2019-02-21 $1.87 $1.94 $1.85 $1.89 315 093
Click to get the best stock tips daily for free!

About Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals. Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase II clinical trials for the treatment of liver cirrhosis, acute-on-chronic liver failure, post-orthotopic liver transplant as a result of hepatitis C virus infection with sust... CNAT Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT